Compare LAES & CMPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LAES | CMPS |
|---|---|---|
| Founded | 2022 | 2020 |
| Country | Switzerland | United Kingdom |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 606.5M | 724.5M |
| IPO Year | 2022 | 2020 |
| Metric | LAES | CMPS |
|---|---|---|
| Price | $2.80 | $8.90 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | $4.00 | ★ $25.38 |
| AVG Volume (30 Days) | ★ 12.2M | 5.0M |
| Earning Date | 03-31-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $93.36 | N/A |
| Revenue Next Year | $43.06 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.99 | $2.25 |
| 52 Week High | $8.71 | $10.21 |
| Indicator | LAES | CMPS |
|---|---|---|
| Relative Strength Index (RSI) | 49.63 | 63.74 |
| Support Level | $2.54 | $5.95 |
| Resistance Level | $2.88 | $10.21 |
| Average True Range (ATR) | 0.23 | 0.77 |
| MACD | 0.05 | 0.14 |
| Stochastic Oscillator | 55.71 | 71.55 |
SEALSQ Corp develops certified secure microcontrollers and implements post-quantum cryptography. The company develops solutions including post-quantum microchips and devices that can be used in a variety of applications, from multi-factor authentication, home automation, and IT network infrastructure to automotive, industrial automation, and control systems. The company's vaultIC range offers a set of ready-to-use secure elements designed to implement embedded security for any kind of device with fast time-to-market and high flexibility. The company's products include VaultIC155, VaultIV18x, VaultIC292, and VaultIC40x. The company generates a majority of its revenue from North America, while it also has its presence in Europe, Middle East & Africa, Asia Pacific, and Latin America.
Compass Pathways PLC is a biotechnology company focused on developing therapies for mental health conditions. Its research centers on a proprietary synthetic psilocybin formulation, COMP360, which is administered alongside psychological support. The company is conducting clinical trials to evaluate the safety and efficacy of this treatment in patients with treatment-resistant depression and other mental health disorders. The company operates in one operating segment.